| Typicality: | 0.373 |
| Saliency: | 0.288 |
| in therapeutic outcomes | 12 | other |
| by optimizing platelet inhibition | 10 | manner |
| trial → assess → improvement | 13 |
| trial → address → the degree of improvement | 5 |
| negative | neutral | positive |
| 0.084 | 0.748 | 0.168 |
| Raw frequency | 18 |
| Normalized frequency | 0.288 |
| Modifier score | 0.500 |
| Perplexity | 266.436 |